Cycles triggered with GnRH agonist: Exploring low-dose HCG for luteal support

Reproductive BioMedicine Online

Volumn 20, Issue 2, 2010, Pages 175-181

  Castillo, J C ^a   Dolz, M ^a   Bienvenido, E ^a   Abad, L ^a   Casan, E M ^a   Bonilla Musoles, F ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

GnRH agonist; GnRH antagonist; HCG; OHSS

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN ANTAGONIST; GONAL-F; HCG-LEPORI; LEUPRORELIN; PROGEFFIK; PROGESTERONE; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEAL CELL; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY OUTCOME; PREGNANCY RATE; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77649211847     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.11.018     Document Type: Article

References (46)

1. Acevedo, B., Gomez-Palomares, J.L., Ricciarelli, E., et al., 2006. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 86, 1682-1687.
2. Albano, C., Smitz, J., Camus, M., et al., 1997. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril. 67, 917-922.
3. Al-lnany, H.G., Abou-Setta, A.M., Aboulghar, M., 2007. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod. Biomed. Online 14, 640-649.
4. Babayof, R., Margalioth, E.J., Huleihel, M., et al., 2006. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum. Reprod. 21, 1260-1265.
5. Balasch, J., Fábregues, F., Tur, R., et al., 1995. Further characterization of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum. Reprod. 10, 1377-1381.
6. Binder, H., Dittrich, R., Einhaus, F., et al., 2007. Update on ovarian hyperstimulation syndrome: part 1 - incidence and pathogenesis. Int. J. Fertil. Womens Med. 52, 11-26.
7. Bodri, D., Guillen, J.J., Galindo, A., et al., 2008. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil. Steril. [Epub ahead of print].
8. Bracero, N.J., Jurema, M.W., Posada, M.N., 2001. Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotrophin (hCG) after the use of ganirelix for in-vitro fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertil. Steril. (Suppl.) S93 (O-254).
9. Casañ, E.M., Raga, F., Bonilla-Musoles, F., et al., 2000. Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. J. Clin. Endocrinol. Metab. 85, 1377-1381.
10. Dhont, M., Van der Straeten, F., De Sutter, P., 1998. Prevention of severe ovarian hyperstimulation by coasting. Fertil. Steril. 70, 847-850.
11. Diedrich, K., Diedrich, C., Santos, E., et al., 1994. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum. Reprod. 9, 788-791.
12. Emperaire, J.C., Parneix, I., Ruffie, A., 2004. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reprod. Biomed. Online 9, 22-27.
13. Engmann, L., DiLuigi, A., Schmidt, D., et al., 2008. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in-vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 89, 84-91.
14. Engmann, L., Siano, L., Schmidt, D., et al., 2006. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod. Biomed. Online 13, 639-644.
15. Golan, A., Ron-el, R., Herman, A., et al., 1989. Ovarian hyperstimulation syndrome: an update review. Obstet. Gynecol. Surv. 44, 430-440.
16. Gonen, Y., Balakier, H., Powell, W., et al., 1990. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in-vitro fertilization. J. Clin. Endocrinol. Metab. 71, 918-922.
17. Griesinger, G., Diedrich, K., Tarlatzis, B.C., et al., 2006. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotropins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod. Biomed. Online 13, 628-638.
18. Griesinger, G., Kolibianakis, E.M., Papanikolaou, E.G., et al., 2007. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonista or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil. Steril. 88, 616-621.
19. Hoff, J.D., Quigley, M.E., Yen, S.S., 1983. Hormonal dynamics at midcycle: a reevaluation. J. Clin. Endocrinol. Metab. 57, 792-796.
20. Hugues, J.N., 2002. Ovarian stimulation for assisted reproductive technologies. In: Vayena, E., Rowe, P.J., Griffin, P.D. (Eds.), Current Practices and Controversies in Assisted Reproduction. World Health Organization, Geneva, Switzerland, pp. 102-125.
21. Humaidan, P., Bredkjaer, H.E., Bungum, L., et al., 2005. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. 20, 1213-1220.
22. Humaidan, P., Bungum, L., Bungum, M., et al., 2006. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod. Biomed. Online 13, 173-178.
23. Imoedemhe, D.A., Sigue, A.B., Pacpaco, E.L., et al., 1991. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in-vitro fertilization. Fertil. Steril. 55, 328-332.
24. Itskovitz, J., Boldes, R., Levron, J., et al., 1991. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril. 56, 213-220.
25. Itskovitz-Eldor, J., Kol, S., Mannaerts, B., 2000. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum. Reprod. 15, 1965-1968.
26. Kol, S., 2003. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum. Reprod. 18, 1557-1558.
27. Kol, S., 2004. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil. Steril. 81, 1-5.
28. Kol, S., Muchtar, M., 2005. Recombinant gonadotrophin-based, ovarian hyperstimulation syndrome-free stimulation of the high responder: suggested protocol for further research. Reprod. Biomed. Online 10, 575-577.
29. Kolibianakis, E.M., Schultze-Mosgau, A., Schroer, A., et al., 2005. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum. Reprod. 20, 2887-2892.
30. Latouche, J., Crumeyrolle-Arias, M., Jordan, D., et al., 1989. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125, 1739-1741.
31. Macklon, N.S., Stouffer, R.L., Giudice, L.C, et al., 2006. The science behind 25 years of ovarian stimulation for in-vitro fertilization. Endocr. Rev. 27, 170-207.
32. Minaretzis, D., Jakubowski, M., Mortola, J.F., et al., 1995. Gonadotropin releasing hormone receptor gene expression in human ovary and granulosa lutein cells. J. Clin. Endocrinol. Metab. 80, 430-434.
33. Nakano, R., Mizuno, T., Kotsuji, F., et al., 1973. 'Triggering' of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstet. Gynecol. Scand. 52, 269-272.
34. Orvieto, R., 2005. Can we eliminate severe ovarian hyperstimulation syndrome? Hum. Reprod. 20, 320-322.
35. Papanicolaou, E.G., Pozzobon, C, Kolibianakis, E.M., et al., 2006. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in-vitro fertilization cycles. Fertil. Steril. 85, 112-120.
36. Parneix, I., Emperaire, J.C, Ruffie, A., et al., 2001. Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin. Gynécol. Obstét. Fertil. 29, 100-105.
37. Peñarrubia, J., Balasch, J., Fâbregues, F., et al., 1998. Human chorionic gonadotropin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum. Reprod. 13, 3315-3318.
38. Revel, A., Casper, R.F., 2001. The use of LHRH agonists to induce ovulation. Infertil. Reprod. Med. Clin. North Am. 12, 105-118.
39. Rizk, B., 2006. Epidemiology of ovarian hyperstimulation syndrome. In: Rizk, B. (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge University Press, pp. 10-42 (Chapter 2).
40. Rizk, B., Smitz, J., 1992. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum. Reprod. 7, 320-327.
41. Romeu, A., Monzó, A., Peiró, T., et al., 1997. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. J. Assist. Reprod. Genet. 14, 518-524.
42. Segal, S., Casper, R.F., 1992. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in-vitro fertilization. Fertil. Steril. 57, 1254-1258.
43. Shapiro, B.S., Daneshmand, S.T., Garner, F.C., et al., 2008. Gonadotropin-releasing hormone agonis combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in-vitro fertilization. Fertil. Steril. 90, 231-233.
44. Sharara, F.I., McClamrock, H.D., 1999. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum. Reprod. 14, 2777-2782.
45. Takekida, S., Deguchi, J., Samoto, T., et al., 2000. Comparative analysis of the effects of gonadotropin-releasing hormone agonist on the proliferative activity, apoptosis, and steroidogenesis in cultured porcine granulosa cells at varying stages of follicular growth. Endocr. 12, 61-67.
46. Veeck, L.L., 1990. The Morphological Assessment of Human Oocytes and Early Concepts. Handbook of the Laboratory Diagnosis and Treatment of Infertility. CRC Press, Boca Raton, FL, pp. 353-369.